Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877136 | 0.81 | MAOB (0.58) | MAOBAPPNR4A2NPC1RAB9A | |
| SCHEMBL557817 | 0.81 | LMNA (0.57) | MAOBAPPCA12CA1CA2 | |
| SCHEMBL3476988 | 0.81 | MAOB (0.61) | MAOBMAOA | |
| SCHEMBL18154523 | 0.80 | APP (0.61) | MAOBAPPNPC1RAB9A | |
| SCHEMBL17810160 | 0.80 | MMP1 (0.49) | MAOBAPPPDE4A | |
| SCHEMBL20848358 | 0.77 | MAOB (0.67) | MAOBAPPCA12CA1CA2 | |
| SCHEMBL6927496 | 0.76 | MAOB (0.66) | MAOBAPPCA12CA1CA2 | |
| SCHEMBL18937890 | 0.76 | MAOB (0.71) | MAOBAPPCA12CA1CA2 | |
| SCHEMBL4380683 | 0.76 | MAOB (0.55) | MAOBPDE4A | |
| SCHEMBL132779 | 0.76 | GRM5 (0.39) | MAOBAPPPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120035102-A9 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110003739-A1 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003739-A1 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | MAOB 129/4885APP 3861/4885CA12 4394/4885 |
| US-20120035102-A9 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | MAOB 129/4885APP 3861/4885CA12 4394/4885 |
| US-20120316200-A1 | PYRIDONE DERIVATIVES | MC1R, MC5R, MCHR1 | MAOB 106/4885APP 2732/4885CA12 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.